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OBJECTIVE—To evaluate the efﬁcacy and safety of a-lipoic acid (ALA) over 4 years in mild-
to-moderate diabetic distal symmetric sensorimotor polyneuropathy (DSPN).
RESEARCH DESIGN AND METHODS—In a multicenter randomized double-blind
parallel-group trial, 460 diabetic patients with mild-to-moderate DSPN were randomly assigned
to oral treatment with 600 mg ALA once daily (n =233) orplacebo(n = 227) for 4 years. Primary
end point was a composite score (Neuropathy Impairment Score [NIS]–Lower Limbs [NIS-LL]
and seven neurophysiologic tests). Secondary outcome measures included NIS, NIS-LL, nerve con-
duction, and quantitative sensory tests (QSTs).
RESULTS—Change in primary end point from baseline to 4 years showed no signiﬁcant
difference between treatment groups (P = 0.105). Change from baseline was signiﬁcantly better
with ALA than placebo for NIS (P = 0.028), NIS-LL (P = 0.05), and NIS-LL muscular weakness
subscore (P = 0.045). More patients showed a clinically meaningful improvement and fewer
showed progression of NIS (P = 0.013) and NIS-LL (P = 0.025) with ALA than with placebo.
Nerve conduction and QST results did not signiﬁcantly worsen with placebo. Globalassessment
of treatment tolerability and discontinuations due to lack of tolerability did not differ between
the groups. The rates of serious adverse events were higher on ALA (38.1%) than on placebo
(28.0%).
CONCLUSIONS—Four-year treatment with ALA in mild-to-moderate DSPN did not inﬂu-
ence the primary composite end point but resulted in a clinically meaningful improvement and
prevention of progression of neuropathic impairments and was well tolerated. Because the pri-
marycompositeendpointdidnotdeterioratesigniﬁcantlyinplacebo-treatedsubjects,secondary
prevention of its progression by ALA according to the trial design was not feasible.
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D
iabetic distal symmetric sensori-
motor polyneuropathy (DSPN) is a
chronic progressive disease affecting
around one-third of the diabetic popula-
tion and accounts for considerable mor-
bidity, increased mortality, and reduced
quality of life (1,2). Recent long-term
studiesintype2diabeticpatients indicate
that the current strategies of intensive dia-
betes therapy or multifactorial cardiovas-
cular risk intervention are not sufﬁcient
to slow the progression of DSPN (3–5).
Thus, effective treatment of DSPN remains
challenging for the physician (1,6).
Basedonthepathogeneticmechanisms
of DSPN, potential disease-modifying
therapeutic approaches have been devel-
oped including antioxidants such as
a-lipoic acid (ALA) (7–9) to diminish in-
creased oxidative stress (10). Other po-
tential modalities include the aldose
reductase inhibitors (11), growth factors
(12), and the protein kinase C-b inhibitor
ruboxistaurin(13).Thesedrugshavebeen
designedtofavorablyinﬂuencetheunder-
lying pathophysiology of the disorder
rather than for symptomatic pain relief.
However, several problems have been en-
countered previously in designing appro-
priate clinical trials in DSPN. Among
these, the most important are as follows:
1) the lack of homogeneity of patients
studied with respect to both the form of
neuropathy and the degree of glycemic
control; 2) different pathogenetic path-
ways, the relative importance of which
may vary intraindividually; 3)s t a g e so f
neuropathy that are too advanced; 4) the
use of end points with rather large vari-
ability between individuals and between
centers; 5) the unknown relevance of
end points used; and 6) study durations
too short to allow for a favorable func-
tional or structural effect (6,14,15).
Treatment with ALA administered
intravenously or orally for several weeks
or months improves neuropathic symp-
toms and deﬁcits (7–9). However, based
on the assumption that a therapeutic
agent may prevent worsening of DSPN
but not cause improvement, clinical trials
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Pathophysiology/Complications
ORIGINAL ARTICLEshouldbeconductedforaminimumperiod
of 3 years to achieve a clinically meaningful
change of two Neuropathy Impairment
Score (NIS) points (16,17). Therefore, we
assessed the efﬁcacy and safety of oral
treatment with 600 mg ALA once daily
in mild-to-moderate DSPN.
RESEARCH DESIGN AND
METHODS—The NeurologicalAssess-
mentofThiocticAcidinDiabeticNeurop-
athy (NATHAN) 1 trial was a multicenter
(36 centersintheU.S.,Canada,and Europe
[Supplementary Materials]), randomized,
double-blind, placebo-controlled, two-
arm, 1:1 allocation ratio, parallel-group
clinical trial using ﬁlm-coated tablets con-
taining600mgALA(ThioctacidHR;MEDA
Pharma, Bad Homburg, Germany) that
were administered once daily or matching
placebo tablets with increased amounts of
cellulose and lactose that were identical in
appearance in diabetic patients with mild-
to-moderateDSPN(18).Thetrialconsisted
of a 2-week screening phase, 6-week pla-
cebo run-in phase, 4-year double-blind
phase, and 4-week washout phase. Ap-
provals wereobtainedfromthelocalethics
committees of all participating centers.
Inclusioncriteriaatthescreeningvisit
were age 18–64 years; type 1 or type 2
diabetes deﬁned by the American Diabe-
tes Association criteria (1997); diabetes
duration $1 year; presence of stage 1 or
2aDSPNattributabletodiabetes(18);sta-
ble insulin regimen, weight, diet, and
physical activity level as judged by the in-
vestigator; NIS–Lower Limbs and seven
nerve conduction tests (NIS-LL+7) score
$97.5th percentile (corresponding to
4.43 transformed score points); NIS-LL
$2 points; one of two abnormalities [ei-
ther 1) abnormal nerve conduction attri-
butes in two separate nerves $99th
percentile for distal latency or #1st per-
centile for nerve conduction velocity or
amplitude or 2) abnormal heart rate dur-
ing deep breathing (HRDB) #1st percen-
tile or total symptom score (TSS) in the
feet ,5 points]; and being of the female
sex and surgically sterilized, $1 year
postmenopausal, or practicing an accept-
able method of contraception.
Exclusion criteria were neuropathies
other than DSPN; myopathy and other
neurologic diseases that may might inter-
fere with the assessment of the severity of
DSPN; previous bilateral sural nerve biop-
sies; peripheral vascular disease with inter-
mittent claudication; foot ulcers; high risk
forvisualloss;psychiatric,psychological,or
behavioral symptoms that would interfere
with the patient’s ability to participate in
the trial; active neoplastic disease except
basal cell carcinoma; uncontrolled atrial
ﬁbrillation; clinically signiﬁcant cardiac,
pulmonary, gastrointestinal, hematologic,
or other endocrine disease; organ trans-
plants; aspartate aminotransferase or ala-
nine aminotransferase .2 times normal;
serum creatinine .1.8 and .1.6 mg/dL
for men and women, respectively; drug or
alcohol abuse within the last year; use of
investigational drug within the last 6
months; severe or anaphylactic reaction
to multiple drugs, sulfur products, or bio-
logicproducts;ketoacidosisorhypoglyce-
mia within the last 3 months resulting in
hospital admission; antioxidant therapy
(.400 IU vitamin E, .200 mg vitamin C,
or .30 mg/day b carotene) or pentoxy-
phylline within the last month; g-linolenic
acidandALA .50mg/daywithinthelast
3 months; history of use of medications
or vitamins known to cause peripheral
neuropathy including but not limited to
use of phenytoin or carbamazepine $15
years or use of .100 mg/day pyridoxine
withinthelast12months;anduseofpain
medications except for standard doses of
salicylates, ibuprofen, indoles, fenamates,
oxicams, or pyrazoles.
Outcomes
The primary outcome measure was a
composite score including the NIS-LL+7
suggested by Dyck et al. (16) including 1)
vibration detection threshold, 2)p e r o -
neal motor nerve conduction velocity
(MNCV), 3) peroneal motor nerve distal
latency, 4) peroneal compound muscle
action potential (CMAP), 5) tibial motor
nervedistallatency,6)suralsensorynerve
action potentialamplitude, and7)change
in HRDB. The primary criterion of efﬁcacy
in the conﬁrmatory analysis was the abso-
lute change in the NIS-LL+7 score ex-
p r e s s e da sn o r m a ld e v i a t e s( n d sf r o m
percentilescorrectingforage and other ap-
plicablevariables)betweenbaseline(mean
of visit during weeks 1 and 2 or last avail-
able value before randomization) and end
point (mean of weeks 191 and 192 or last
available value after randomization).
Secondary outcome measures included
the NIS, NIS-LL, Neuropathy Symptoms
and Change (NSC) score, TSS, cooling
detection threshold, heat pain response
slope (0.5–5.0), tibial nerve CMAP and
MNCV, sural sensory nerve action poten-
tial latency, and sensory nerve conduction
velocity (SNCV). In a response/progres-
sion analysis after 2 and 4 years, a clini-
callymeaningfulresponsewasdeﬁnedasa
decrease in NIS or NIS-LL by $2 points,
respectively, while clinically meaningful
progression was deﬁned as an increase in
NIS or NIS-LL by $2 points, respectively
(16,17).
Duplicate measurements of these
measures within 1 week were performed
at baseline,after 2 years, andafter 4 years,
whereas single measurements were car-
ried out at screening and after 6 months,
1 year, and 3 years except for the NIS and
NSC, which were assessed as single as-
sessments at screening and thereafter at
6-month intervals, and the TSS and foot
inspection, assessed at 3-month intervals.
The NIS is the sum score of exami-
nations of muscle weakness, reﬂex loss,
touch pressure, vibration, joint position
and motion, and pinprick of index ﬁnger
and great toe and is scored for both sides
of the body (19). The NSC scores (num-
ber, severity, and change) are derived
from answers to 38 questions (muscle
weakness, questions 1–19; sensation,
questions 20–29; and autonomic symp-
toms, questions 30–38) (7). Experienced,
trained, and certiﬁed (by P.J.D. and col-
leagues)physiciansevaluatedtheNISand
NSC. Study physicians had participated
in training sessions and actual examina-
tion of patients under observation using
a formal certiﬁcation process. The nerve
conduction, quantitative sensory tests
(QSTs), and autonomic tests were per-
formedbytrained andcertiﬁed personnel
(byP.A.L.,W.J.L.,P.J.D.,andcolleagues).
All results were interactively evaluated by
the Reading and Quality Assurance Cen-
ters (at Mayo Clinic and Health Partners).
Eligibility,baselineconditions,waveforms,
stimulus response patterns, and test values
were also assessed.
Safety measures included monitor-
ing of adverse events, vital signs, weight,
12-lead resting electrocardiogram, chest
X-ray at baseline, concomitant medica-
tion,globalassessmentoftolerability,and
physical examination. Laboratory tests
including blood chemistry, hematology,
blood glucose, and HbA1c were performed
at screening, baseline, and 2-month (1st
year), 3-month (2nd year), and 6-month
(3rd year) intervals.
Randomization
Screened patients were assigned a unique
ﬁve-digit number. Randomized patients
were additionally assigned a four-digit
randomizationnumberatbaseline.Patients
were assigned to the two treatment groups
accordingtoarandomizationlistgenerated
by the Biostatistics Department of MEDA
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Ziegler and AssociatesPharma. The random allocation was bal-
anced using an undisclosed block size
of six. The investigators and the monitor
receivedsealedenvelopestoenabledecod-
ing the individual blinded treatment in
case of emergency.
Statistical analysis
Conﬁrmatory analysis. The following
hypothesis was tested: H0:mT=mPv s .
H1:mT mP, where mTa n dmPd e n o t e
the mean change in NIS-LL+7 tests from
baseline to end point in the ALA and pla-
cebo groups, respectively. A two-way
ANOVA including the factors treatment
and center was performed. Variances were
allowed to differ between treatments. De-
grees of freedom were derived according
toKenward-Rogers.A95%CIforthetreat-
ment difference based on least squares
(LS) estimates from the model without
interactions was calculated. A second
model including treatment and center in-
teraction was ﬁtted explanatorily.
Interim analysis. An interim analysis
was performed as soon as the 2-year
data of most subjects were available. The
complete table part of the study had been
provided to and assessed by an indepen-
dent supervisory committee. The decision
oncontinuationofthe studywasbasedon
the conﬁrmatory test of the primary vari-
able. At P , 0.005, the study would have
been stopped. To ensure a global type 1
error of 5%, the error level for the ﬁnal
analysis was set to a2 = 0.0452 according
to the  Sidák (20) inequality.
Depending on the structure of data,
either contingency tables [n (%)] or de-
scriptive statistics (n,m e a n ,S D ,m e d i a n ,
range, quartiles) were presented for time
courses and changes from baseline. Sec-
ondary end points were analyzed by
applying a Wilcoxon Mann-Whitney test.
Adverse events were coded according
to the World Health Organization-Adverse
Reactions Terminology (ART). Global in-
cidences on preferred term and body
system class level were calculated based
on different causality ﬁlters. Vital and
laboratory variables were screened for
notableindividualandtrend-likechanges.
Sample size calculation. We used a con-
servative approach to suggest that treat-
ment with ALA may prevent worsening of
DSPN but not necessarily cause improve-
ment (16). A clinically meaningful treat-
ment difference of 2.0 nds for the changes
frombaselineforNIS-LL+7testsandstatis-
ticalerrorprobabilitiesa=0.05andb=0.1
were assumed. Based on a two-sided t test,
the following scenarios forSDs and sample
size per group (n) were considered: SD
3.57, n = 68; SD 4, n = 86; SD 5, n =1 3 3 ;
SD 6, n =1 9 1 ;S D7 ,n = 211. To account
for a relatively high dropout rate expected
in this long-term study, randomization of
250 patients per arm was proposed. Anal-
ysis of the intention-to-treat population
was primary for all efﬁcacy variables. Ho-
mogeneity of baseline characteristics was
investigated by exploratory statistical tests
based on the intention-to-treat population
on selected baseline variables.
RESULTS
Patient disposition, clinical
characteristics, HbA1c, and
vital signs
The patient disposition throughout the
trialaccordingtotheCONSORTStatement
2010 ﬂow diagram (21) is shown in Fig. 1.
The demographic variables and outcome
measures at baseline in both groups are
shown in Table 1. As a sign of homoge-
neity, no signiﬁcant differences among
the groups were noted for any of the pa-
rameters listed except for HRDB (P =
0.0193).
Mean HbA1c decreased from baseline
by0.6761.41%intheALAgroupandby
0.48 6 1.46% on placebo after 2 years.
After 4 years, HbA1c declined compared
with baseline by 0.62 6 1.59% with ALA
and by 0.60 6 1.78% during placebo
without signiﬁcant differences between
thegroups(P=0.9313after4years).After
4 years, systolic blood pressure decreased
by0.1616.1mmHgintheALAgroupand
by 0.2 6 16.5 mmHg in the group given
placebo (P = 0.9770). The corresponding
Figure 1—Patient disposition.
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NATHAN 1 trial: ALA in polyneuropathyreductionsindiastolicbloodpressurewere
3.5 6 11.1mmHgfor ALAcomparedwith
2.7 6 9.8 for placebo (P =0 . 5 1 2 1 ) .H e a r t
ratedeclined by2.6 6 10.9bpm withALA
treatment and by 2.1 6 10.4 bpm in the
placebo group after 4 years compared with
baseline (P = 0.7115). Weight increased
slightly by 1.3 6 5.4 kg in the ALA-treated
group compared with 0.9 6 8.6 in the
placebo group (P = 0.6157).
The changes in the clinical neuropa-
thy scores and nerve function tests from
baseline to 2 and 4 years are summarized
inTable2.TheNIS-LL+7compositescore
decreased after 4 years compared with
baseline on ALA (LS mean 20.45) and
increased on placebo (LS mean 10.34)
without reaching statistical signiﬁcance
between the groups (ALA-placebo differ-
ence in LS means 0.78 [95% CI 20.16 to
1.73]; P = 0.105). After 4 years, NIS im-
proved signiﬁcantly on ALA and worsened
on placebo (P = 0.028) while the differ-
ences from baseline between the groups
reached borderline signiﬁcance for the
pinprick test of NIS (P = 0.074) and
NIS-LL (P = 0.0505). The muscularweak-
ness subscore of NIS-LL improved signif-
i c a n t l yo nA L Aa n dd e t e r i o r a t e do n
placebo (P = 0.045). No signiﬁcant differ-
ences between the groups after 4 years
were noted for the NIS-LL subscores
sensory function and reﬂexes. Response
analysis after 4 years revealed that the per-
centages of clinical responders (decrease
in NIS or NIS-LL by $2p o i n t s )w e r e
higher while at the same time those of
progressors (increase in NIS or NIS-LL
by $2 points) were lower on ALA com-
pared with placebo. This difference was
statistically signiﬁcant for both NIS (P =
0.013) and NIS-LL (P = 0.025). The NSC
scores for weakness number and severity,
respectively, improved on ALA and wors-
ened on placebo (P = 0.005 and P =
0.008).Nosigniﬁcantdifferencesbetween
both groups after 4 years were noted for
the nerve conduction parameters, QST,
HRDB, or TSS.
Safety analysis
The incidences of treatment-emergent ad-
verseevents(TEAEs)were214 (92.6%) on
ALA and 203 (90.2%) on placebo, respec-
tively. Two (0.9%) patients on ALA and
one (0.7%) patient on placebo discon-
tinued study treatment as a result of lack
of tolerability (i.e., because of an adverse
event with “likely” causal relationship to
study medication as judged by the inves-
tigator). Analysis of TEAEs by the body
system class showed that heart rate,
rhythmdisorders,andmyocardial,endo-
cardial, pericardial, valvular, and urinary
system disorders tended to be more fre-
quentonALAthanonplacebo(Supplemen-
tary Table 1). No signiﬁcant differences
in the incidences of the individual car-
diovascular disorders were observed
between the groups (Supplementary
Table2).CorrectedQTinterval(QTc)pro-
longation .60 ms was signiﬁcantly more
frequent on placebo than that on ALA
(10 [5.0%] vs. 3 [1.4%]; P = 0.0497).
Global assessment of treatment tolerability
by investigators and patients showed no
differences between the groups (Supple-
mentary Table 3).
Serious adverse events (SAEs) oc-
curred in 88 (38.1%) patients in the
ALA group and in 63 (28.0%) of those
receivingplacebo.TheincidenceofSAEsin
the ALA group versus that in the placebo
group was 31 (13.4%) vs. 20 (8.9%),
respectively, (P = 0.125) for cardiovascular
disorders;5(2.2%)vs.7(3.1%)(P=0.528)
for cerebrovascular disorders; 20 (8.7%)
vs. 13 (5.7%) (P = 0.235) for infections;
23 (10.0%) vs. 14 (6.2%) for inﬂicted in-
juries (including surgical interventions,
coronary angiography or angioplasty,
and fractures; P = 0.144); and 3 (1.3%)
vs. 6 (2.7%) (P = 0.294) for deaths.
CONCLUSIONS—The results of this
longest randomized clinical trial ever
conducted in DSPN demonstrate that
4-yeartreatmentwiththeantioxidantALA
did not inﬂuence a composite score con-
sisting of the NIS-LL+7 but improved
neuropathic impairments scored by the
NIS and NIS-LL, particularly small ﬁber
and muscular function. The lack of im-
provement in the composite score was
predominantly due to the fact that nerve
conduction deﬁcits in the placebo-treated
group did not progress. Thus, secondary
prevention of progression of the compos-
ite end point by treatment with ALA was
not readily achievable. In contrast, a re-
sponse analysis of clinically meaningful
improvement and progression in these
scores by at least two points (16,17) re-
vealed that the percentages of NIS and
NIS-LL responders with mild-to-moderate
DSPN were signiﬁcantly higher on ALA,
whereas the progressors were more fre-
quent with placebo. To achieve these fa-
vorable effects, 4 years of treatment using
Table 1—Clinical characteristics of the intention-to-treat population at baseline
ALA Placebo P
n 230 224
Age (years) 53.3 6 8.3 53.9 6 7.6 0.3607
Sex (% male) 66.1 67.0 0.8430
BMI (kg/m
2) 29.7 6 6.1 29.8 6 6.1 0.9226
Heart rate (bpm) 76.3 6 12.3 74.6 6 12.6 0.1603
Type 1/type 2 diabetes 27.4 / 72.6 21.0 / 79.0 0.1111
Diabetes duration (years) 13.3 (0.8–56.1) 13.5 (0.9–46.7) 0.4190
Neuropathy duration (years) 3.0 (0.0–25.4) 3.2 (0.0–21.1) 0.2588
Insulin treatment 58.9 55.1 0.4170
HbA1c 8.9 6 1.8 8.8 6 1.9 0.6354
Fasting blood glucose (mmol/L) 11.1 6 4.68 10.9 6 4.26 0.6529
Nephropathy 11.7 12.0 0.5935
Retinopathy 45.5 43.6 0.6833
Neuropathy stage 1/stage 2a 11.3 / 88.7 9.8 / 90.2 0.6074
NIS-LL+7 (nds) 17.1 6 8.4 16.8 6 8.0 0.6740
NIS (points) 12.7 6 8.6 12.2 6 7.8 0.5062
NIS-LL (points) 9.8 6 5.6 9.5 6 5.3 0.6087
Peroneal MNCV (m/s) 38.5 6 5.03 38.1 6 6.48 0.4957
Sural SNAP (mV) 2.49 6 3.38 2.43 6 3.21 0.8387
Vibration perception threshold (JND) 21.27 6 3.18 21.21 6 3.52 0.8393
Cold detection threshold (JND) 17.86 6 5.14 17.58 6 5.33 0.5765
Heart rate deep breathing (bpm) 7.26 6 5.44 8.59 6 6.59 0.0193
NSC weakness (number) 0.06 6 0.30 0.03 6 0.23 0.2353
NSC weakness (severity) 0.10 6 0.56 0.04 6 0.31 0.1613
TSS (points) 2.4 6 1.9 2.6 6 1.8 0.2752
Data are means 6 SD, median (range), or %. P values derived from x
2 test for binary data and from t tests
otherwise. JND, just noticeable difference; SNAP, sensory nerve action potential.
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Ziegler and Associates600 mg ALA once daily were necessary.
Safety analysis showed that SAEs were
slightly more frequent in patients receiv-
ing ALA, but more deaths occurred in the
placebo group.
Similar to recent multicenter trials in
DSPN (22), only a minor progression of
the various measures of DSPN was ob-
served in the placebo group over 4 years
in the present trial. Therefore, improve-
ment rather than slowing of progression
was required for most outcomes to dem-
onstrate efﬁcacy. Because nerve conduc-
tion attributes did not deteriorate in the
placebo group and did not improve with
ALA, the composite primary end point
could not be expected to ameliorate de-
spite the improvement in neuropathic
deﬁcits. One reason for the lack of deteri-
oration of nerve conduction attributes
during placebo treatment could be the re-
d u c t i o ni nm e a nH b A 1c by 0.6% in this
group. However, the calculation of the
sample size and trial duration was based
on the assumption that a treatment effect
slows the progression of DSPN without
improving it (16). This concept has been
challenged by recent ﬁndings, suggesting
that DSPN progresses very slowly or may
even improve in placebo-treated patients
participating in randomized clinical trials
(11,13,22). A progressive improvement
in neuropathic symptoms over 1 year was
observed in placebo-administered patients
withmildsymptomaticDSPN(22).Inare-
cent multicenter study, patients with mild-
to-moderate DSPN randomized to placebo
showed an improvement of 2.0 6 8.0 m/s
in summed median and sural SNCV after
1 year, which was associated with im-
provements in glycemic control and se-
rum triglyceride levels (23). Dyck et al.
(15) assessed clinimetric performance of
DSPNendpointsinsingleandmulticenter
trials. They concluded that the main rea-
sons why it is difﬁcult to demonstrate
monotonic worsening of neuropathic
endpointsappearstobeaveryslowwors-
ening of DSPN, improvement of symp-
toms and signs in the placebo group,
and measurement noise. Demonstrating
disease progression in DSPN trials may
be more likely when 1) patients with de-
velopingratherthanestablishedDSPNare
selected, 2) type 1 diabetic patients are
preferentially recruited, 3) patients are se-
lected who cannot achieve ideal glycemic
control, 4) end points chosen are known
to show monotonic worsening, and 5)a
restricted number of centers and expert
examiners are used.
The reasons for the disparity between
the effects of ALA on neuropathic deﬁcits
and nerve conduction or QST are not un-
derstood, but the same pattern was ob-
served in the short-term Symptomatic
Diabetic Neuropathy (SYDNEY) trial
over 3 weeks (7). The mechanisms of the
improvement in neuropathic impairments
may be related to an improvement in
nerve blood ﬂow mediated by the antiox-
idant action of the drug. In the Irbesartan
and Lipoic Acid in Endothelial Dysfunc-
tion (ISLAND) study,oraladministration
of 300mgALAperdaytopatientswiththe
metabolic syndrome resulted in a signiﬁ-
cant increase in endothelium-dependent
brachial artery ﬂow–mediated vasodilation
Table 2—Changes in clinical neuropathy scores and nerve function tests from baseline to 2 and 4 years
2 Years 4 Years
ALA Placebo ALA Placebo
n 214 207 215 207
Composite score
NIS-LL+7 (nds) 20.40 6 4.92 0.19 6 4.74 20.37 6 5.59* 0.29 6 5.37
NIS and subscores
NIS 20.54 6 6.62 0.12 6 6.13 20.68 6 6.44† 0.61 6 6.61
NIS pinprick 20.06 6 1.48 20.05 6 1.44 20.07 6 1.60‡ 0.05 6 1.43
NIS-LL 20.38 6 4.52 0.03 6 4.22 20.34 6 4.48§ 0.43 6 4.49
NIS-LL sensory function 20.34 6 3.02 20.09 6 2.92 20.12 6 3.01 0.10 6 2.89
NIS-LL muscular weakness 20.15 6 1.66 0.05 6 1.85 20.21 6 1.57† 0.17 6 2.12
NIS-LL reﬂexes 0.10 6 1.63 0.07 6 1.57 0.03 6 1.75 0.16 6 1.80
NIS responders 37.9 35.2 41.1† 30.0
NIS unchanged 35.6 32.4 29.7† 31.9
NIS progressors 26.5 32.4 29.2† 38.1
NIS-LL responders 34.7 34.8 35.6† 29.0
NIS-LL unchanged 42.0 35.2 40.2† 36.2
NIS-LL progressors 23.3 30.0 24.2† 34.8
Nerve function tests
Peroneal MNCV (m/s) 0.04 6 3.89 0.18 6 3.99 20.35 6 4.23 20.06 6 4.07
Sural SNAP (mV) 20.00 6 2.17 20.07 6 1.96 20.20 6 2.34 20.15 6 2.43
Foot VPT (JND) 0.47 6 2.12 0.58 6 2.11 0.87 6 2.35 0.76 6 2.38
Cold detection threshold (JND) 0.65 6 3.56 0.87 6 3.33 1.12 6 3.96 1.28 6 3.43
Heart rate deep breathing (bpm) 20.68 6 3.39 21.06 6 3.23 20.67 6 4.44¶ 21.35 6 3.72
Neuropathic symptoms
NSC weakness (number) 20.02 6 0.30 0.04 6 0.42 20.04 6 0.26† 0.04 6 0.42
NSC weakness (severity) 20.03 6 0.40 0.03 6 0.48 20.05 6 0.39† 0.04 6 0.50
TSS 20.27 6 2.46 20.04 6 2.16 20.22 6 2.42 20.21 6 2.45
Dataaremeans6SDor%.AllPvaluescalculatedvs.placebo,withtwo-wayANOVAforNIS-LL+7andWilcoxonMann-Whitneytestsotherwise.JND,justnoticeable
difference; SNAP, sensory nerve action potential; VPT, vibration perception threshold. *P = 0.105. †P , 0.05. ‡P = 0.074. §P = 0.0505. ¶P = 0.087.
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interleukin-6 and plasminogen activator-1
compared with placebo after 4 weeks, sug-
gesting that the drug may improve endo-
thelial dysfunction via anti-inﬂammatory
and antithrombotic mechanisms (23).
Interestingly, prevention of endothelial
dysfunction via activation of AMP-
activated protein kinase by ALA was pos-
tulated as a possible mechanism to explain
the weight loss achieved after 20 weeks
of ALA treatment in obese Korean sub-
jects (24).
There is no ﬁrm explanation for the
higher incidence of SAEs on ALA than
placebo, given that only two patients on
ALA and one patient on placebo discon-
tinued study treatment due to adverse
events with “likely” causal relationship to
study medication as judged by the inves-
tigator. Moreover, when SAEs due to car-
diovascular/cerebrovascular disorders/
procedures anddeathsweresummarized,
34 (14.7%) patients on ALA and 27
(12.0%)patientsonplacebowereaffected
(P = 0.394). On the other hand, QTc pro-
longation .60 ms was signiﬁcantly more
frequent on placebo than on ALA (5.0 vs.
1.4%; P = 0.0497) and more deaths were
observed with placebo than with ALA
(3 [1.3%] vs. 6 [2.7%]). Thioctacid is an
over-the-counter drug that has been
widely prescribed in Germany for de-
cades, and postmarketing surveillance
data sources from Germany showed low
rates of adverse drug reactions compara-
ble with those reported in previous clin-
ical trials (25).
In conclusion, 4-year treatment with
ALA in mild-to-moderate DSPN was well
toleratedandwasassociatedwithimprove-
ment of neuropathic impairments but not
nerve conduction attributes. Therefore,
the primary composite end point did not
change signiﬁcantly. The clinical progres-
sionofDSPNintheplacebogroupwithin
the setting of this randomized clinical trial
withgoodretentionofpatientsthroughout
a 4-year period was relatively slow. Hence,
prediction of a treatment effect aimed at
halting the progression of DSPN based
on epidemiologic data indicating signif-
icant progression may not be appropri-
ate. The designs of future trials in similar
diabetic populations should anticipate a
long-term stable neuropathic condition.
For demonstration of efﬁcacy, the drug
or combinations of drugs that impact
the different nerve ﬁbers affected in
DSPN that are tested in the future must
achieve a clinically relevant neurologic
improvement.
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